Close Menu

More articles about Companion Diagnostics

Spartan Bioscience and Nanosphere are each working with academic research groups to determine the utility of their CYP2C19 tests for gauging response to Plavix at the point of care.

At AACC, Rheonix presented three research studies demonstrating its integrated sample prep and PCR testing platform. In addition, the company reiterated its intent to seek regulatory clearance in the US for a warfarin sensitivity genotyping test by the end of the year; followed by a regulatory submission in China for an HPV test.

The firm intends to file for FDA clearance of the test, which would run on its CARD molecular diagnostics system.

Medco Research Institute announced this week that it is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor for the treatment of heartburn. The study will involve genetic testing to establish which patients can respond to Plavix.

The two-year study will assess the impact of genetic information on determining warfarin dosage and changes in the rate of adverse events when beginning a warfarin treatment regimen.

An ACCF/AHA panel has alerted doctors to evidence gaps regarding the clinical utility of genetic testing to administer Plavix, but not all cardiologists agree with the group's recommendations.

The French firm also said it has received $564,000 in funding for the project.

Aeterna Zentaris and Almac are entering into a research collaboration to develop a companion diagnostic to be used with Aeterna Zentaris' potential cancer drug.

CDC's GAPPNet has launched several new online resources for gathering information on available genomic technologies, including a searchable database of genomic applications and a new open-access journal that publishes evidence reviews and summary articles on the validity and utility of genetic tests.

Steven Murphy, founder of the Personalized Medicine Group, last week introduced GeneticHub as an online resource for people around the country seeking doctors with genetic expertise and a high-volume clinical laboratory with appropriate certifications to conduct genetic testing.

The slew of PGx abstracts presented by the drug giant at the annual oncology meeting highlighted its “focused approach to cancer drug development through the identification and validation of molecular targets,” Pfizer said.

The accreditation allows the division, which is increasingly focused on providing biomarkers for the development of companion diagnostics, to support later phases of drug development.

NICE's recommendation for NHS to pay for AstraZeneca's non-small cell lung cancer drug Iressa in EGFR mutation-positive patients marks the second personalized medicine product to be funded in the UK after Herceptin was approved in 2002 for HER2-overexpressing breast cancer patients.

The 13 drugs for which CVS Caremark customers will have the option to sign up for genetic testing includes a range of treatments for cancer, HIV, and other indications, but the anticoagulant warfarin is not on the list.

In an out-of-court settlement, Qiagen and Roche decided they both would have distribution rights to TheraScreen tests from Qiagen subsidiary DxS.

Hal Barron, Genentech's chief medical officer, said that "by using [Dako's] diagnostics to help identify the right patients" who will benefit from treatment, Genentech hopes to make Herceptin "the first targeted option for advanced HER2-positive stomach cancer."

Affomix and the PGx Centre will develop reagents for the quantitative multiplex profiling of candidate biomarkers that may allow clinicians to predict and evaluate how patients respond to novel anti-atherosclerotic agents.

The settlement ends a dispute over distribution rights to two DxS assays, with both firms having the right to distribute the products.

In launching Precision Health Solutions, Medco will expand access to pharmacogenetic tests to all its customers.

The company will collaborate with the University of Oregon to develop companion diagnostic tests to identify adverse effects on mitochondria from antiviral drugs.

Pages

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.